期刊
WOMEN'S HEALTH AND DISEASE
卷 1205, 期 -, 页码 245-253出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2010.05673.x
关键词
sex; women; gender; HRT; estrogen; brain; hormones; aging; Alzheimer's; dementia; fMRI; brain imaging
类别
资金
- Medical Research Council [G84/6518] Funding Source: Medline
- Department of Health [RP-PG-0606-1045] Funding Source: Medline
- Alzheimers Research UK [ART-ESG2006-3] Funding Source: researchfish
- Medical Research Council [G0400061] Funding Source: researchfish
- National Institute for Health Research [RP-PG-0606-1045] Funding Source: researchfish
- MRC [G84/6518, G0400061] Funding Source: UKRI
Previous studies in postmenopausal women have reported that estrogen treatment (ET) modulates the risk for developing Alzheimer's disease (AD). It has recently been hypothesized that there may be a critical period around the time of menopause during which the prescription of ET may reduce the risk of developing AD in later life. This effect may be most significant in women under 49 years old. Furthermore, prescription of ET after this point may have a neutral or negative effect, particularly when initiated in women over 60-65 years old. In this paper, we review recent studies that use in vivo techniques to analyze the neurobiological mechanisms that might underpin estrogen's effects on the brain postmenopause. Consistent with the critical period hypothesis, these studies suggest that the positive effects of estrogen are most robust in young women and in older women who had initiated ET around the time of menopause.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据